New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More

Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough

By Rameen Kasana | October 02, 2025, 9:45 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most promising biotech stocks to buy according to hedge funds. During the second quarter, Generate Investment Management Ltd acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) through the purchase of 12,000 shares of the company’s stock. According to a recent disclosure with the SEC, the firm’s investment in the company is approximately $6,300,000 now.

While the company’s returns don’t seem quite compelling, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has what only a few have. In a noteworthy update, the company posted a Phase 2 COURAGE study on September 17, and to much surprise, garetosmab demonstrated exceptional efficacy in treating fibrodysplasia ossificans progressiva.

Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week

We already know that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) maintains a solid presence in the United States, particularly through the construction of a new manufacturing facility in Rensselaer, along with the deal signed with Fujifilm earlier in April. Given the strong Dupixent growth and a healthy balance sheet, the company is well-positioned for a bright future.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a New York-based company specializing in medicines for treating various diseases. Incorporated in 1988, the company offers EYLEA, myopic choroidal neovascularization, neovascular glaucoma, and Dupixent.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.

Latest News

1 hour
8 hours
Oct-01
Oct-01
Sep-30
Sep-30
Sep-29
Sep-29
Sep-29
Sep-29
Sep-29
Sep-26
Sep-25
Sep-24
Sep-23